Publications

Journal Article Epublish
Open access — free full text available
Open access
Electronic publication date
June 29, 2026

View on Pubmed.gov 42370102 | View on doi.org 10.1016/j.ero.2... (full text)

Healthcare providers' awareness and knowledge of recommendations on cardiovascular risk management in people with rheumatic and musculoskeletal diseases: a survey study.

Search for publications in this journal EULAR Rheumatol Open - 2(1):362-369

EULAR CardioVascular Involvement in Inflammatory Arthritis (CVIIA) Study Group

Abstract

OBJECTIVES

Patients with rheumatic and musculoskeletal diseases (RMDs) have increased cardiovascular (CV) risk. European Alliance of Associations for Rheumatology (EULAR) issued CV risk management recommendations in 2015/2016 and 2022, but healthcare providers' (HCPs') awareness and their implementation in clinical practice are unknown. This study aims to assess HCP awareness of the EULAR CV recommendations and barriers to their implementation.

METHODS

A cross-sectional survey was distributed via social media to all HCPs involved in treating patients with RMDs. Data on demographics, awareness of the 2015/2016 and 2022 recommendations, and perceived implementation barriers were collected. The survey was endorsed by the EULAR Study Group on Cardiovascular Involvement in Inflammatory Arthritis.

RESULTS

Of 226 complete responses, 54% were hospital rheumatologists and 36% had 5 to 15 years of experience. Overall, 67% knew both recommendation sets. Knowledge scores were higher among those aware of both recommendations compared with those who knew neither. Most respondents (83%) recognised that platelet inhibitors are not recommended for primary prevention; only 8% identified the role of low systemic lupus erythematosus disease activity. Nearly all (96%) endorsed corticosteroid minimisation. Half viewed rheumatologists as primarily responsible for CV risk management; 16% knew the 1.5 multiplication factor for rheumatoid arthritis risk scoring. None correctly noted that antihypertensives and statins can be used as in the general population. Barriers included time constraints (62%), insufficient knowledge (37%), and lack of local protocols (14%).

CONCLUSIONS

Despite moderate awareness of EULAR CV recommendations, substantial knowledge gaps and practical barriers persist, indicating the need for focused education and improved clinical pathways to enhance CV risk management in RMD care.

References

Aaramaa H.K., Mars N., Helminen M., Kerola A.M., Palomäki A., Eklund K.K., et al. Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases. Semin Arthritis Rheum. 2024;65

Adelowo O., Omokhowa A., Ochiagha O., Uhunmwangho CU. Comorbidities in Nigerian patients with rheumatoid arthritis. Clin Rheumatol. 2024;43(1):23–28.

Alghalawin L.S., Alomar M., Al Bassam S., Alhamdan A.A., Anan H., Altaweel M., et al. Incidence rate of cardiovascular events in rheumatoid arthritis: an observational cohort study in Saudi Arabia. J Multidiscip Healthc. 2024;17:3357–3370.

Ahn J.K., Hwang J., Choi C.B., Seo GH. Risk of acute myocardial infarction, stroke, and venous thromboembolism among patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in South Korea: a nationwide population-based study. Joint Bone Spine. 2023;90(2)

Conflict of interest statement

All authors declare they have no competing interests.

MeSH

Specialties

Copyright

© 2026 The Author(s).